Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals.

Published on Aug 26, 2021in Frontiers in Immunology7.561
· DOI :10.3389/FIMMU.2021.722766
Yosuke Hirotsu20
Estimated H-index: 20
,
Kenji Amemiya17
Estimated H-index: 17
+ 4 AuthorsMasao Omata129
Estimated H-index: 129
(UTokyo: University of Tokyo)
Sources
Abstract
Background null Vaccines against severe acute respiratory syndrome coronavirus 2 can trigger acquired immunity in infection-naive individuals and offer a path toward ending the coronavirus disease pandemic that began in 2019. However, the kinetics of early antibody responses in vaccinated individuals remain poorly understood. null Method null We followed BNT162b2 mRNA-vaccinated health care workers (HCWs, N=108) including 103 infection-naive and five previously infected individuals. A total of 763 blood samples were collected weekly or hourly basis before and after vaccination. Serological analysis of anti-spike and anti-nucleocapsid antibodies was performed. null Results null Seroconversion occurred in all infection-naive HCWs 3 weeks after the first dose (just before the second vaccination) and a marked boosting effect was observed at 4 weeks (1 week after the second dose). Among previously infected HCWs with pre-existing antibodies against the spike protein, a remarkable boosting effect was observed during the first week after vaccination, and a further increase in antibody titres was observed after the second dose. In one previously infected patient, daily blood sampling was conducted. Antibody titres began to increase 96 hours (4 days) after the first dose. null Conclusion null The BNT162b2 mRNA vaccine remarkably enhanced antibody responses after the second dose in infection-naive individuals and after the first dose in previously infected HCWs of all ages and genders. Antibody titres decreased slightly after the 5th week post-vaccination. The robust boosting effect of immunisation suggests that increased antibody titres following exposure to the virus may restrict viral replication, prolong the incubation period, or lessen the severity of disease.
📖 Papers frequently viewed together
20216.60Cells
References32
Newest
#1Alessio Mazzoni (UniFI: University of Florence)H-Index: 18
Last. Francesco Annunziato (UniFI: University of Florence)H-Index: 84
view all 22 authors...
The characterization of the adaptive immune response to COVID-19 vaccination in individuals who recovered from SARS-CoV-2 infection may define current and future clinical practice. To determine the effect of two doses BNT162b2 mRNA COVID-19 vaccination schedule in individuals who recovered from COVID-19 (COVID-19 recovered) compared to naive subjects, we evaluated SARS-CoV-2 Spike-specific T and B cell responses, as well as specific IgA, IgG, IgM and neutralizing antibodies titers in 22 individu...
Source
#1Ezgi Hacisuleyman (HHMI: Howard Hughes Medical Institute)H-Index: 1
#2Caryn R Hale (HHMI: Howard Hughes Medical Institute)H-Index: 4
Last. Robert B. Darnell (HHMI: Howard Hughes Medical Institute)H-Index: 91
view all 15 authors...
Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern. In a cohort of 417 persons who had received the second dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine at least 2 weeks previously, we identified 2 women with vaccine breakthrough infection. Despite evidence of vaccine efficacy in both women, symptoms of coronavirus disease 2019 developed, and they tested positive for SARS-CoV-2 by polymerase-chain-reaction testing. Viral ...
Source
#1Kanika Vanshylla (University of Cologne)H-Index: 6
#2Veronica Di Cristanziano (University of Cologne)H-Index: 13
Last. Florian Klein (University of Cologne)H-Index: 35
view all 26 authors...
Summary Understanding antibody-based SARS-CoV-2 immunity is critical for overcoming the COVID-19 pandemic and informing vaccination strategies. We evaluated SARS-CoV-2 antibody dynamics over 10 months in 963 individuals who predominantly experienced mild COVID-19. Investigating 2,146 samples, we initially detected SARS-CoV-2 antibodies in 94.4% individuals, with 82% and 79% exhibiting serum and IgG neutralization, respectively. Approximately 3% of individuals demonstrated exceptional SARS-CoV-2-...
Source
We aimed to investigate novel emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages in Japan that harbor variants in the spike protein receptor-binding domain (RBD). The total nucleic acid contents of samples from 159 patients with coronavirus disease 2019 (COVID-19) were subjected to whole genome sequencing. The SARS-CoV-2 genome sequences from these patients were examined for variants in spike protein RBD. In January 2021, three family members (one aged in their 40s an...
Source
#1Julien Favresse (Université de Namur)H-Index: 13
#2Jean-Louis BayartH-Index: 7
Last. Jonathan Douxfils (Université de Namur)H-Index: 30
view all 6 authors...
Abstract Objectives Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimal dose regimen in this population has not been clearly studied. The CRO-VAX HCP study aims at investigate the early antibody response in a population of healthcare professionals having received two doses of the BNT162b2 mRNA COVID-19 vaccine. Methods The CRO-VAX HCP study is a multicenter, prospective, interventio...
Source
#1Sandile Cele (UKZN: University of KwaZulu-Natal)H-Index: 6
#2Inbal Gazy (UKZN: University of KwaZulu-Natal)H-Index: 12
Last. Alex Sigal (UKZN: University of KwaZulu-Natal)H-Index: 25
view all 22 authors...
SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations [1, 2] and may reduce the efficacy of current vaccines targeting the spike glycoprotein [3]. Here, using a live virus neutralization assay (LVNA), we compared neutralization of a non-VOC variant versus the 501Y.V2 variant using plasma collected from adults hospitalized with COVID-19 from two South African infection waves, with the second wave dominated by 501Y.V2 infections. Sequencing demonstrated that infectio...
Source
#1Lisa Müller (HHU: University of Düsseldorf)H-Index: 9
#2Marcel Andree (HHU: University of Düsseldorf)H-Index: 10
Last. Heiner Schaal (HHU: University of Düsseldorf)H-Index: 27
view all 19 authors...
BACKGROUND: The SARS-CoV-2 pandemic has led to the development of various vaccines. Real-life data on immune responses elicited in the most vulnerable group of vaccinees over 80 years old is still underrepresented despite the prioritization of the elderly in vaccination campaigns. METHODS: We conducted a cohort study with two age groups, young vaccinees below the age of 60 and elderly vaccinees over the age of 80, to compare their antibody responses to the first and second dose of the BNT162b2 C...
Source
#1Rishi R. Goel (UPenn: University of Pennsylvania)H-Index: 17
#2Sokratis A. Apostolidis (UPenn: University of Pennsylvania)H-Index: 23
Last. E. John WherryH-Index: 115
view all 31 authors...
Novel mRNA vaccines for SARS-CoV-2 have been authorized for emergency use. Despite their efficacy in clinical trials, data on mRNA vaccine-induced immune responses are mostly limited to serological analyses. Here, we interrogated antibody and antigen-specific memory B cells over time in 33 SARS-CoV-2 naive and 11 SARS-CoV-2 recovered subjects. SARS-CoV-2 naive individuals required both vaccine doses for optimal increases in antibodies, particularly for neutralizing titers against the B.1.351 var...
Source
#1Joseph E. Ebinger (Cedars-Sinai Medical Center)H-Index: 12
#2Justyna Fert-Bober (Cedars-Sinai Medical Center)H-Index: 12
Last. Kimia Sobhani (Cedars-Sinai Medical Center)H-Index: 10
view all 12 authors...
In a cohort of BNT162b2 (Pfizer-BioNTech) mRNA vaccine recipients (n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection (n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection (n = 228). Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar betw...
Source
#1Lorenzo Azzi (University of Insubria)H-Index: 8
#2Daniele FocosiH-Index: 25
Last. Fabrizio Maggi (University of Insubria)H-Index: 38
view all 5 authors...
Source
Cited By4
Newest
#1Zabrina L. Brumme (SFU: Simon Fraser University)H-Index: 56
#2Francis M Mwimanzi (SFU: Simon Fraser University)H-Index: 2
Last. Mark A. Brockman (SFU: Simon Fraser University)H-Index: 48
view all 43 authors...
Humoral responses to COVID-19 vaccines in people living with HIV (PLWH) remain incompletely understood. We measured circulating antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, ACE2 displacement and live viral neutralization activities one month following the first and second COVID-19 vaccine doses in 100 adult PLWH and 152 controls. All PLWH were receiving suppressive antiretroviral therapy, with median CD4+ T-cell counts of 710 (IQR 525-935) cells/mm 3 . Na...
Source
#1Jean-Louis BayartH-Index: 7
#2Jonathan DouxfilsH-Index: 30
Last. Vincent GerinH-Index: 2
view all 15 authors...
Data about the long-term duration of antibodies after SARS-CoV-2 vaccination are still scarce and are important to design vaccination strategies. In this study, 231 healthcare professionals received the two-dose regimen of BNT162b2. Of these, 158 were seronegative and 73 were seropositive at baseline. Samples were collected at several time points. The neutralizing antibodies (NAbs) and antibodies against the nucleocapsid and the spike protein of SARS-CoV-2 were measured. At day 180, a significan...
Source
#1Zhenxiao Ren (Kobe University)H-Index: 2
#2Koichi Furukawa (Kobe University)H-Index: 4
Last. Yasuko Mori (Kobe University)H-Index: 35
view all 18 authors...
Abstract null The situation of the COVID-19 pandemic in Japan is drastically changing in the 2nd year, 2021, due to the appearance of SARS-CoV-2 variants of concern and the roll-out of mass vaccination. In addition to PCR diagnosis, periodic seroepidemiologic surveillance is important to analyze the epidemic situation. In this study, we analyzed the rate of seropositivity for the SARS-CoV-2 N and S antigens in Hyogo prefecture, Japan in August 2021. Sera collected from people who received a heal...
Source
#1Yosuke HirotsuH-Index: 20
#2Masao Omata (UTokyo: University of Tokyo)H-Index: 129
Abstract null null Background null The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) circulates in the world and acquires mutations during evolution. To identify the new emergent variants, the surveillance of the variants of concern (VOC) and variants of interest (VOI) is ongoing. This study aimed to determine how the transition of viral lineage occurred by stationary genome analysis in Yamanashi, Japan. null null null Methods null We performed the whole genome sequencing using SA...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.